Shares of NantHealth Inc (NYSE:NH) have been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.55.
NH has been the topic of several analyst reports. Jefferies Group LLC restated a “buy” rating and issued a $5.50 price target (down previously from $8.00) on shares of NantHealth in a research note on Monday, June 19th. BidaskClub upgraded shares of NantHealth from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 target price (down from $8.00) on shares of NantHealth in a report on Monday, August 21st.
A number of large investors have recently added to or reduced their stakes in NH. TIAA CREF Investment Management LLC boosted its position in NantHealth by 68.6% in the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after buying an additional 8,217 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of NantHealth during the first quarter worth approximately $457,000. Bank of America Corp DE raised its stake in shares of NantHealth by 366.4% during the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock worth $125,000 after buying an additional 19,694 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in shares of NantHealth during the first quarter worth approximately $998,000. Finally, National Planning Corp bought a new stake in shares of NantHealth during the second quarter worth approximately $473,000.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/11/nanthealth-inc-nh-receives-8-55-average-price-target-from-analysts.html.
Shares of NantHealth (NYSE NH) traded down 0.24% during trading on Friday, reaching $4.11. The company had a trading volume of 427,898 shares. The stock has a 50 day moving average of $3.60 and a 200 day moving average of $4.13. The stock’s market capitalization is $501.20 million. NantHealth has a 52-week low of $2.60 and a 52-week high of $15.80.
NantHealth (NYSE:NH) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.32. The business had revenue of $26.23 million for the quarter, compared to analyst estimates of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. NantHealth’s revenue was down 16.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.15) EPS. Equities research analysts forecast that NantHealth will post ($0.70) EPS for the current year.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.